Cover Image
市場調查報告書

EB病毒(EBV)感染疾病 : 開發中產品分析

Epstein-Barr Viral Infections - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 303579
出版日期 內容資訊 英文 71 Pages
訂單完成後即時交付
價格
Back to Top
EB病毒(EBV)感染疾病 : 開發中產品分析 Epstein-Barr Viral Infections - Pipeline Review, H2 2016
出版日期: 2016年08月10日 內容資訊: 英文 71 Pages
簡介

EB病毒(EBV)又稱為人類第四型皰疹病毒,是皰疹病毒系的一種,同時也是最常見的人類病毒之一。EBV一般是透過體液傳染,會在性交中藉由血液、精液傳染,也會透過輸血或組織移植擴散。EBV傳染病主要的症狀有倦怠感和發熱、喉嚨發炎、頭部的淋巴結腫脹、脾臟肥大化、肝臟腫脹、皮疹等。

本報告提供全球各國治療EB病毒(EBV)感染疾病所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查,並將結果概述為以下內容。

目錄

簡介

  • 分析範圍

EB病毒(EBV)感染疾病概要

治療藥的開發

  • EBV感染疾病開發中產品:概要
  • EBV感染疾病開發中產品:比較分析

各企業開發中的EBV感染疾病治療藥

大學/研究機關研究中的EBV感染疾病治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

EBV感染疾病治療藥:開發中的產品一覽(各企業)

EBV感染疾病治療藥:研究中的產品一覽(各大學/研究機關)

EBV感染疾病開發治療藥的企業

  • Arno Therapeutics, Inc.
  • Cell Medica Limited
  • Epiphany Biosciences, Inc.
  • Genocea Biosciences, Inc.
  • Humabs BioMed SA
  • Molplex Ltd.
  • Omeros Corporation
  • Savoy Pharmaceuticals, Inc.
  • Theravectys SA
  • Vironika, LLC
  • ViroStatics srl

EBV感染疾病:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

EBV感染疾病治療藥:開發暫停的產品

EBV感染疾病相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8337IDB

Summary

Global Markets Direct's, 'Epstein-Barr Viral Infections - Pipeline Review, H2 2016', provides an overview of the Epstein-Barr Viral Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Epstein-Barr Viral Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epstein-Barr Viral Infections and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Epstein-Barr Viral Infections
  • The report reviews pipeline therapeutics for Epstein-Barr Viral Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Epstein-Barr Viral Infections therapeutics and enlists all their major and minor projects
  • The report assesses Epstein-Barr Viral Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Epstein-Barr Viral Infections

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Epstein-Barr Viral Infections
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Epstein-Barr Viral Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Epstein-Barr Viral Infections Overview
  • Therapeutics Development
    • Pipeline Products for Epstein-Barr Viral Infections - Overview
    • Pipeline Products for Epstein-Barr Viral Infections - Comparative Analysis
  • Epstein-Barr Viral Infections - Therapeutics under Development by Companies
  • Epstein-Barr Viral Infections - Therapeutics under Investigation by Universities/Institutes
  • Epstein-Barr Viral Infections - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Epstein-Barr Viral Infections - Products under Development by Companies
  • Epstein-Barr Viral Infections - Products under Investigation by Universities/Institutes
  • Epstein-Barr Viral Infections - Companies Involved in Therapeutics Development
    • Arno Therapeutics, Inc.
    • Cell Medica Limited
    • Epiphany Biosciences, Inc.
    • Genocea Biosciences, Inc.
    • Humabs BioMed SA
    • Molplex Ltd.
    • Omeros Corporation
    • Savoy Pharmaceuticals, Inc.
    • Theravectys SA
    • Vironika, LLC
    • ViroStatics srl
  • Epstein-Barr Viral Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AR-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for EBV Associated PTLD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Infectious Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Systemic Lupus Erythematosus and Epstein-Barr Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Viral Infections Post-HSCT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target Calcineurin A for EBV associated post transplant B cell lymphoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CMD-003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Epstein-Barr virus (virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Epstein-Barr virus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for Epstein-Barr Viral Infection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MVA vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Infectious Mononucleosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit EBNA1 for Epstein-Barr Virus (EBV) Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Target GPR183 for Osteoporosis and Epstein-Barr Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit EBNA1 for Epstein-Barr Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Epstein-Barr Virus and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • valomaciclovir stearate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Viroprev - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Epstein-Barr Viral Infections - Dormant Projects
  • Epstein-Barr Viral Infections - Product Development Milestones
    • Featured News & Press Releases
      • Mar 25, 2014: University of Birmingham launches trial to fight cancer caused by a common virus
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Epstein-Barr Viral Infections, H2 2016
  • Number of Products under Development for Epstein-Barr Viral Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Epstein-Barr Viral Infections - Pipeline by Arno Therapeutics, Inc., H2 2016
  • Epstein-Barr Viral Infections - Pipeline by Cell Medica Limited, H2 2016
  • Epstein-Barr Viral Infections - Pipeline by Epiphany Biosciences, Inc., H2 2016
  • Epstein-Barr Viral Infections - Pipeline by Genocea Biosciences, Inc., H2 2016
  • Epstein-Barr Viral Infections - Pipeline by Humabs BioMed SA, H2 2016
  • Epstein-Barr Viral Infections - Pipeline by Molplex Ltd., H2 2016
  • Epstein-Barr Viral Infections - Pipeline by Omeros Corporation, H2 2016
  • Epstein-Barr Viral Infections - Pipeline by Savoy Pharmaceuticals, Inc., H2 2016
  • Epstein-Barr Viral Infections - Pipeline by Theravectys SA, H2 2016
  • Epstein-Barr Viral Infections - Pipeline by Vironika, LLC, H2 2016
  • Epstein-Barr Viral Infections - Pipeline by ViroStatics srl, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Epstein-Barr Viral Infections - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Epstein-Barr Viral Infections, H2 2016
  • Number of Products under Development for Epstein-Barr Viral Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top